Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | SLC29A1 | Q99808 | 2/20 | 0.40 |
| ▸ | PDE4A | P27815 | 1/20 | 0.39 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.39 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.39 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.39 |
| ▸ | ABL1 | P00519 | 2/20 | 0.38 |
| ▸ | RIN1 | Q13671 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6572841 | 0.86 | SLC29A1 (0.47) | ADORA3SLC29A1PDE4APDE4BPDE4C | |
| SCHEMBL6572836 | 0.86 | SLC29A1 (0.47) | ADORA3SLC29A1PDE4APDE4BPDE4C | |
| SCHEMBL6576713 | 0.76 | SLC29A1 (0.48) | ADORA3SLC29A1 | |
| SCHEMBL6576715 | 0.76 | SLC29A1 (0.48) | ADORA3SLC29A1 | |
| SCHEMBL2290883 | 0.68 | HIF1A (0.66) | SLC29A1 | |
| SCHEMBL2290876 | 0.68 | HIF1A (0.66) | SLC29A1 | |
| SCHEMBL17865919 | 0.67 | SLC29A1 (0.55) | ADORA3SLC29A1PDE4APDE4BPDE4C | |
| SCHEMBL6573836 | 0.66 | ADORA3 (0.51) | ADORA3SLC29A1 | |
| SCHEMBL5849139 | 0.66 | SLC29A1 (0.69) | ADORA3SLC29A1 | |
| SCHEMBL5849132 | 0.66 | SLC29A1 (0.69) | ADORA3SLC29A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1090019-B1 | ADENOSINE DERIVATIVES | GLAXO GROUP LTD (GB) | 2004-09-29 | — | — | EP | disclosed |
| US-6677316-B2 | TREATING ISCHEMIA, CARDIOVASCULAR DISORDERS, STROKE, PAIN, NERVOUS SYSTEM DISORDERS OR SLEEP APNEA; ADENOSINE A1 RECEPTOR AGONIST; 2-(3-(TERT-BUTYL)-1,2,4-OXADIAZOL-5-YL)-5-(6-(ISOBUTYLAMINO)-9H-PURIN-9-YL) TETRAHYDROFURAN-3,4-DIOL | SMITHKLINE BEECHAM CORPORATION | 2004-01-13 | — | — | US | disclosed |
| US-20030096788-A1 | Adenosine derivatives | GLAXO WELLCOME INC. | 2003-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030096788-A1 | Adenosine derivatives | ADORA3, ADORA2A, ADORA1 | ADORA3 1/4885SLC29A1 201/4885PDE4A 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.